home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.15 -0.19 (-0.81%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals ↗

May 10, 2024

Via Benzinga

Catalyst's New CEO Has Big Ideas For The Small Biotech ↗

May 10, 2024

Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.

Via Investor's Business Daily

CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter ↗

May 08, 2024

The company doubled Wall Street's earnings views, but sales came in short.

Via Investor's Business Daily

Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

May 08, 2024

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals ↗

March 27, 2024

Via Benzinga

Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts ↗

March 07, 2024

Via Benzinga

Earnings Preview For Catalyst Pharmaceuticals ↗

February 27, 2024

Via Benzinga

Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024

May 01, 2024

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

April 22, 2024

The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

March 28, 2024

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

March 27, 2024

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List ↗

March 27, 2024

Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.

Via InvestorPlace

7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗

March 18, 2024

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

Via InvestorPlace

Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

March 18, 2024

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

Via Investor's Business Daily

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

March 13, 2024

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio ↗

March 10, 2024

While small-cap stocks can be incredibly risky, they also offer the potential for dramatic gains you won’t find with the big dogs.

Via InvestorPlace

Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗

March 05, 2024

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.

Via Investor's Business Daily

3 Biopharma Stocks You Don't Want to Miss in the New Bull Market ↗

March 05, 2024

All three have exciting programs on the way.

Via The Motley Fool

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

March 05, 2024

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Top 3 Health Care Stocks You May Want To Dump In Q1 ↗

February 29, 2024

As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 28, 2024

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

February 27, 2024

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

February 21, 2024

Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety...

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

February 14, 2024

The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months ↗

January 22, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Stanley Black & Decker, Inc.

Via Benzinga

Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances ↗

January 18, 2024

With our improving economy, you need to invest in these top biotech stocks that are looking to strike gold this year.

Via InvestorPlace

Topics Economy

3 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

January 15, 2024

These companies are still in the early innings of their growth potential.

Via The Motley Fool

Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024 ↗

January 14, 2024

With multiple drugs on the market and revenue ramping up, the sky's the limit.

Via The Motley Fool

Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering

January 09, 2024

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com